Absorption; Chemicals Clinical Trial
— BBAOfficial title:
A Pilot Study to Determine the Bioavailability of Oral Beta-Aminoisobutyric Acid (BAIBA) Ingestion
Verified date | April 2022 |
Source | Lindenwood University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Think of this section as your research "elevator pitch." Please briefly describe the question(s) or issues you are addressing with your research (limited to 100 words). You will be able to provide information on specific outcomes, hypothesis, or related analysis in a following question. Beta-amino isobutyric acid (BAIBA) is a myokine produced in skeletal muscle and has been shown to impact how our body metabolizes fuel. We seek to determine the bioavailability of different doses of orally ingested beta-aminoisobutyric acid (BAIBA).
Status | Completed |
Enrollment | 12 |
Est. completion date | February 1, 2022 |
Est. primary completion date | February 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - All participants will be between the ages of 18-50 years - All participants will be required to abstain from taking any amino acid (i.e., BCAAs, creatine, - beta-alanine, carnitine, etc.) for 14 days prior to beginning this study and for the entire duration -of the study - Body mass index between 18.5 - 29.9 kg/m2 - Report accumulating at least 30 minutes of physical activity three days per week - All participants will be determined to be healthy through completion of a detailed health history questionnaires Exclusion Criteria: - Are less than 18 or greater than 50 years of age. Participants younger than 18 are excluded due to necessity of parental consent. Participants greater than 50 years old are excluded due to the anticipated age-related changes that occur in digestive function, medication use, and other - associated confounding comorbidities. - Have a body mass index < 18.5 and > 29.9 kg/m2. Any participant with a BMI > 29.9 kg/m2 must have a body fat percentage below 30% to be eligible. - No individuals with a BMI above 32.0 kg/m2 will be eligible, irrespective of their body composition. - Have a fasting capillary glucose (-30 minutes) level > 110 mg/dL on two separate occasions. - Currently smoke or have quit smoking within the past six months - Are currently following a ketogenic diet or a very low-carbohydrate diet for the past 30 days. - Any individual who is currently being treated for or diagnosed with a cardiac, respiratory, circulatory, musculoskeletal, metabolic, obesity, immune, autoimmune, psychiatric, hematological, neurological or endocrinological disorder or disease will be excluded. - Report accumulating less than 30 minutes of physical activity per day for at least three days per week. - Do not or are not willing to abstain from alcohol, nicotine and caffeine for 12 hours prior to each visit will be excluded - Do not or are not willing to abstain from exercise for 24 hours prior to each visit will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | Lindenwood University | Saint Charles | Missouri |
Lead Sponsor | Collaborator |
---|---|
Lindenwood University | NNB Nutrition |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma concentrations of BAIBA. | Plasma concentrations of BAIBA. | 4 hours | |
Secondary | Complete Blood Count | Plasma and serum indicators of health | 4 hours | |
Secondary | Comprehensive Metabolic Panel | Plasma and serum indicators of health | 4 hours | |
Secondary | Adverse Events | Incidence and associations of reported adverse events | 4 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04078646 -
Influence of Proteins on the Bioavailability of Carotenoids
|
N/A | |
Completed |
NCT04355286 -
Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study
|
Phase 1 | |
Completed |
NCT03807050 -
Safety and Pharmacokinetics of Phaffia Rhodozyma Astaxanthin
|
N/A | |
Active, not recruiting |
NCT02227615 -
Absorption of Mango in Healthy Individuals
|
N/A | |
Completed |
NCT05277376 -
Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial
|
Phase 3 | |
Completed |
NCT05032807 -
Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation
|
Phase 1 | |
Completed |
NCT05076890 -
Hemp 15 mg & 50 mg Capsule Absorption
|
N/A | |
Completed |
NCT03433040 -
17OHP-C Dosing Among Obese Pregnant Women
|
Phase 3 |